^
Association details:
| Biomarker: | MTOR L1433S + EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFRT790M-mutant non–small cell lung cancer
Published date:
07/06/2021
Excerpt:
The MTORL1433S mutation was oncogenic in Ba/F3 models and showed resistance to osimertinib...in NCI-H1975 cells harboring the MTORL1433S mutation...Osimertinib in combination with mTOR inhibitors abrogated acquired resistance to osimertinib....MTORL1433S- and EGFRL858R/T790M-mutant NSCLC cells were sensitive to osimertinib plus mTOR inhibitors.
DOI:
https://doi.org/10.1016/j.jtho.2021.06.013
